Universite Claude Bernard Lyon 1;Netris Pharma;Institut National de la Sante et de la Recherche Medicale;Centre Leon Berard;Centre National de la Recherche Scientifique
发明人:
Ducarouge, Benjamin,Goldschneider, David,Redavid, Anna Maria Rita,Gibert, Benjamin,Mehlen, Patrick
申请号：
AU2018205730
公开号：
AU2018205730A1
申请日:
2018.01.05
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1 /netrin-1 receptors interaction or netrin-1 -mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.
